Global Pharmaceutical Continuous Manufacturing Market 2023-2029

Global Pharmaceutical Continuous Manufacturing Market 2023-2029

For decades, pharmaceutical firms have manufactured their products in batches. To streamline production, manufacturers have begun to apply continuous manufacturing technologies to the pharmaceutical production process. Continuous manufacturing is a method for manufacturing pharmaceutical products from end-to-end on a single, uninterrupted production line. This continuous production eliminates built-in production gaps and can shorten manufacturing times from months to days. Where batch manufacturing requires transporting, testing, and re-feeding materials from one process to the next, continuous processes execute all testing, feeding, and processing inline. The global pharmaceutical continuous manufacturing market was estimated at USD 1,778 million in 2022 and is expected to hit USD 5,241 million by 2029, registering a CAGR of 16.7% from 2023 to 2029 as per the latest market estimates.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical continuous manufacturing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, drug type, source, and region. The global market for pharmaceutical continuous manufacturing can be segmented by product: active pharmaceutical ingredients (APIs), finished dosage form (FDF). According to the research, the APIs segment had the largest share in the global pharmaceutical continuous manufacturing market. Pharmaceutical continuous manufacturing market is further segmented by drug type: large molecules, small molecules. In 2022, the small molecules segment made up the largest share of revenue generated by the pharmaceutical continuous manufacturing market. Based on source, the pharmaceutical continuous manufacturing market is segmented into: in-house, outsourced. Among these, the in-house segment was accounted for the highest revenue generator in 2022. On the basis of region, the pharmaceutical continuous manufacturing market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).

Market Segmentation
By product: active pharmaceutical ingredients (APIs), finished dosage form (FDF)
By drug type: large molecules, small molecules
By source: in-house, outsourced
By region: Asia Pacific, Europe, North America, Rest of the World (RoW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including Abbott Laboratories, Ajinomoto Althea, Inc., Almac Group, Applikon Biotechnology B.V. (Getinge AB), Cipla Limited, Continuus Pharmaceuticals, Inc., Corden Pharma GmbH (International Chemical Investors S.E.), Eli Lilly and Company, Eppendorf SE, FUJIFILM Holdings Corporation, GEA Group AG, Glatt GmbH, GSK plc, Hovione Limited, Johnson & Johnson, L.B. Bohle Maschinen und Verfahren GmbH, Lonza Group AG, Merck KGaA, Novartis AG, Pall Corporation, Pfizer Inc., Recipharm AB, SEQENS SAS, Shanghai Pharmaceuticals Holding Co., Ltd., Shionogi & Company, Limited, SK biotek Ireland Limited, Syntegon Technology GmbH, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, WuXi Biologics Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Scope of the Report

• To analyze and forecast the market size of the global pharmaceutical continuous manufacturing market.
• To classify and forecast the global pharmaceutical continuous manufacturing market based on product, drug type, source, region.
• To identify drivers and challenges for the global pharmaceutical continuous manufacturing market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pharmaceutical continuous manufacturing market.
• To identify and analyze the profile of leading players operating in the global pharmaceutical continuous manufacturing market.


Why Choose This Report
• Gain a reliable outlook of the global pharmaceutical continuous manufacturing market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.